MYRIAD INTERNATIONAL GMBH – Trademark Portfolio

Entity Type: 16

MYRIAD INTERNATIONAL GMBH holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ENDOPREDICT. The owner is based in COLOGNE.

BUILDING S19, NATTERMANNALLEE 1

COLOGNE 50829 , DE

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

MYRIAD INTERNATIONAL GMBH's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does MYRIAD INTERNATIONAL GMBH have?

MYRIAD INTERNATIONAL GMBH has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does MYRIAD INTERNATIONAL GMBH file in?

MYRIAD INTERNATIONAL GMBH files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are MYRIAD INTERNATIONAL GMBH's most well-known trademarks?

MYRIAD INTERNATIONAL GMBH's registered trademark portfolio includes well-known marks such as ENDOPREDICT. These are among 1 currently registered trademark in the portfolio.

What is MYRIAD INTERNATIONAL GMBH's trademark registration success rate?

MYRIAD INTERNATIONAL GMBH has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.